-
-
-
-
-
-
-
Armata Pharmaceuticals, Inc. (ARMP) Misses Q3 EPS by 24c
-
-
-
-
-
-
-
Armata Pharma (ARMP) Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Armata Pharmaceuticals (ARMP)
408,353 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

